Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 1/Phase 2 Study Of CP-751,871 In Subjects With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors (ESFT)

    Summary
    EudraCT number
    2007-004486-17
    Trial protocol
    GB   DE   NL   ES   FR   IT  
    Global end of trial date
    24 Oct 2012

    Results information
    Results version number
    v1(current)
    This version publication date
    09 Mar 2016
    First version publication date
    01 Aug 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    A4021020
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00560235
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Pfizer Inc.
    Sponsor organisation address
    235 E 42nd Street, New York, United States, NY 10017
    Public contact
    Pfizer ClinicalTrials.gov Call Center , Pfizer Inc. , 1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
    Scientific contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc. , 1 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Jun 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    24 Oct 2012
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to define the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of CP-751,871 in adolescents (10-18 years) and to define the efficacy of CP-751,871 in terms of objective response rate, in subjects 10 years and older with relapsed or refractory ESFT.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    18 Mar 2008
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Efficacy
    Long term follow-up duration
    2 Years
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 5
    Country: Number of subjects enrolled
    United Kingdom: 13
    Country: Number of subjects enrolled
    France: 23
    Country: Number of subjects enrolled
    Germany: 23
    Country: Number of subjects enrolled
    Italy: 22
    Country: Number of subjects enrolled
    Australia: 4
    Country: Number of subjects enrolled
    United States: 29
    Country: Number of subjects enrolled
    Canada: 4
    Country: Number of subjects enrolled
    Chile: 8
    Country: Number of subjects enrolled
    Brazil: 4
    Country: Number of subjects enrolled
    Israel: 3
    Worldwide total number of subjects
    138
    EEA total number of subjects
    86
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    13
    Adolescents (12-17 years)
    65
    Adults (18-64 years)
    60
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Subjects were recruited separately for Phase 1 and Phase 2. A total of 138 subjects were assigned to received study treatment (31 subjects for Phase 1 and 107 subjects for Phase 2).

    Pre-assignment
    Screening details
    Subjects were enrolled in 66 centres of Spain, France, United Kingdom, Germany and Italy. Study started from 18 Mar 2008 and completed on 24 Oct 2012.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Figitumumab Dose Escalation (Phase 1)
    Arm description
    Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.
    Arm type
    Experimental

    Investigational medicinal product name
    Rapamycin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

    Investigational medicinal product name
    Figitumumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Figitumumab 20 milligram per kilogram (mg/kg) IV administered every 4 weeks (1 cycle). If no dose-limiting toxicity (DLT) was identified in the 20-mg/kg cohort, dose escalation proceeded to 30-mg/kg.

    Arm title
    Figitumumab Dose Extension (Phase 1B)
    Arm description
    Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.
    Arm type
    Experimental

    Investigational medicinal product name
    Rapamycin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

    Investigational medicinal product name
    Figitumumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Figitumumab 20 mg/kg or 30 mg/kg IV administered every 4 weeks (1 cycle).

    Arm title
    Figitumumab 30 mg/kg (Phase 2)
    Arm description
    Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.
    Arm type
    Experimental

    Investigational medicinal product name
    Rapamycin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

    Investigational medicinal product name
    Figitumumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    Figitumumab 30 mg/kg IV administered every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal.

    Number of subjects in period 1
    Figitumumab Dose Escalation (Phase 1) Figitumumab Dose Extension (Phase 1B) Figitumumab 30 mg/kg (Phase 2)
    Started
    10
    21
    107
    Completed
    2
    2
    10
    Not completed
    8
    19
    97
         'Discontinued '
    8
    19
    96
         'Ongoing at Date of Cut-Off '
    -
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Figitumumab Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.

    Reporting group title
    Figitumumab Dose Extension (Phase 1B)
    Reporting group description
    Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

    Reporting group title
    Figitumumab 30 mg/kg (Phase 2)
    Reporting group description
    Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.

    Reporting group values
    Figitumumab Dose Escalation (Phase 1) Figitumumab Dose Extension (Phase 1B) Figitumumab 30 mg/kg (Phase 2) Total
    Number of subjects
    10 21 107 138
    Age categorical
    Units: Subjects
        10 to <13 years
    2 3 17 22
        13 to <18 years
    3 13 30 46
        18 to <30 years
    5 5 43 53
        30 to <41 years
    0 0 10 10
        >=41 years
    0 0 7 7
    Gender categorical
    Units: Subjects
        Female
    4 7 40 51
        Male
    6 14 67 87

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Figitumumab Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab intravenous (IV) administration every 4 weeks (1 cycle). Oral rapamycin could have been added as salvage therapy.

    Reporting group title
    Figitumumab Dose Extension (Phase 1B)
    Reporting group description
    Figitumumab IV administration every 4 weeks (1 cycle). Oral rapamycin at 2 to 4 mg/day could have been added as salvage therapy.

    Reporting group title
    Figitumumab 30 mg/kg (Phase 2)
    Reporting group description
    Figitumumab administration every 4 weeks (1 cycle) for up to 12 cycles, unless unacceptable toxicity or subject withdrawal. Oral rapamycin could have been added as salvage therapy.

    Subject analysis set title
    Figitumumab 20 mg/kg Dose Escalation (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle).

    Subject analysis set title
    Figitumumab 30 mg/kg Dose Escalation (Phase 1)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

    Subject analysis set title
    Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

    Primary: Objective Response Rate (ORR)

    Close Top of page
    End point title
    Objective Response Rate (ORR) [1] [2]
    End point description
    Percentage of subjects with objective response based on assessment of confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as complete disappearance of all target and non-target disease and no new lesions. PR was defined as greater than or equal to (>=) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. This analysis included all enrolled subjects with Ewing's sarcoma family of tumors (ESFT) and who started treatment with figitumumab.
    End point type
    Primary
    End point timeframe
    Baseline and every cycle (4 weeks) for up to 6 cycles
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive data was planned to be reported for this end point.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This end point  was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.
    End point values
    Figitumumab 30 mg/kg (Phase 2)
    Number of subjects analysed
    106 [3]
    Units: percentage of subjects
        number (confidence interval 95%)
    14.2 (8.1 to 22.3)
    Notes
    [3] - Number of evaluable subjects for this end point.
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS)

    Close Top of page
    End point title
    Progression-Free Survival (PFS) [4]
    End point description
    PFS was the time in months from start date to date of first documentation of progression, death due to any cause or symptomatic deterioration (global deterioration of health status requiring discontinuation of treatment). This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab.
    End point type
    Secondary
    End point timeframe
    Baseline and every cycle (4 weeks), until progression or death
    Notes
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This end point  was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.
    End point values
    Figitumumab 30 mg/kg (Phase 2)
    Number of subjects analysed
    107
    Units: months
        median (confidence interval 95%)
    1.9 (1.8 to 2.1)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS) [5]
    End point description
    Time in months from enrollment to death. For subjects who were alive, overall survival was censored at the last contact. This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab.
    End point type
    Secondary
    End point timeframe
    Baseline and every 2 cycles (8 weeks), until death or up to 6 cycles after date of enrollment
    Notes
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This end point  was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.
    End point values
    Figitumumab 30 mg/kg (Phase 2)
    Number of subjects analysed
    107
    Units: months
        median (confidence interval 95%)
    8.9 (7.2 to 10.8)
    No statistical analyses for this end point

    Secondary: Maximum Observed Plasma Concentration (Cmax)

    Close Top of page
    End point title
    Maximum Observed Plasma Concentration (Cmax)
    End point description
    The pharmacokinetic (PK) analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively.
    End point type
    Secondary
    End point timeframe
    Cycle 1 and Cycle 5: 1 hour post-infusion on Day 1
    End point values
    Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Number of subjects analysed
    4
    6
    21
    Units: milligrams per liter (mg/L)
    geometric mean (geometric coefficient of variation)
        Cycle 1 (n=4, 6, 21)
    513.2 ( 42 )
    1075 ( 21 )
    975.6 ( 26 )
        Cycle 5 (n=2, 2, 8)
    729 ( 47 )
    1133 ( 9 )
    1043 ( 47 )
    No statistical analyses for this end point

    Secondary: Minimum Observed Plasma Trough Concentration (Cmin)

    Close Top of page
    End point title
    Minimum Observed Plasma Trough Concentration (Cmin)
    End point description
    Cmin is the concentration at the end of treatment cycle (next cycle predose). The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results. Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.
    End point type
    Secondary
    End point timeframe
    Cycle 6: predose on Day 1
    End point values
    Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Number of subjects analysed
    1 [6]
    1 [7]
    7 [8]
    Units: mg/L
        geometric mean (geometric coefficient of variation)
    389 ( 99999 )
    345 ( 99999 )
    283.6 ( 53 )
    Notes
    [6] - Number of subjects evaluated for measure.
    [7] - Number of subjects evaluated for measure.
    [8] - Number of subjects evaluated for measure.
    No statistical analyses for this end point

    Secondary: Plasma Concentration at End of Infusion (Cendinf)

    Close Top of page
    End point title
    Plasma Concentration at End of Infusion (Cendinf)
    End point description
    The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively.
    End point type
    Secondary
    End point timeframe
    Cycle 1 Day 2 and Cycle 5 Day 1
    End point values
    Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Number of subjects analysed
    4
    6
    21
    Units: mg/L
    geometric mean (geometric coefficient of variation)
        Cycle 1 (n=4, 6, 21)
    513.2 ( 42 )
    1075 ( 21 )
    975.6 ( 26 )
        Cycle 5 (n=2, 2, 8)
    729 ( 47 )
    1133 ( 9 )
    1043 ( 47 )
    No statistical analyses for this end point

    Secondary: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    Close Top of page
    End point title
    Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
    End point description
    The dosing interval was 1 cycle (4 weeks) in this study. The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results. Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.
    End point type
    Secondary
    End point timeframe
    Cycle 5: 1 hour post-infusion on Day 1
    End point values
    Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Number of subjects analysed
    1 [9]
    1 [10]
    6 [11]
    Units: milligram*hour per liter (mg*hr/L)
        geometric mean (geometric coefficient of variation)
    423000 ( 99999 )
    475000 ( 99999 )
    302900 ( 46 )
    Notes
    [9] - Number of subjects evaluated for measure.
    [10] - Number of subjects evaluated for measure.
    [11] - Number of subjects evaluated for measure.
    No statistical analyses for this end point

    Secondary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Close Top of page
    End point title
    Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
    End point description
    AUClast is the area under the plasma concentration time-curve from zero to the last measured concentration. The PK analysis set included all enrolled subjects who started treatment and who had sufficient samples to provide interpretable results; n=number of subjects evaluable for this measure at specified time points for each arm group, respectively. Here "99999" in the geometric coefficient of variation (CV) signifies not available (NA). Geometric CV was not calculated as only 1 subject was evaluated for this time point.
    End point type
    Secondary
    End point timeframe
    Cycle 1 and Cycle 5: 1 hour post-infusion on Day 1
    End point values
    Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Number of subjects analysed
    4
    6
    21
    Units: mg*hr/L
    geometric mean (geometric coefficient of variation)
        Cycle 1 (n=3, 5, 16)
    187200 ( 37 )
    338800 ( 16 )
    343000 ( 25 )
        Cycle 5 (n=1, 1, 6)
    423000 ( 99999 )
    509000 ( 99999 )
    310800 ( 46 )
    No statistical analyses for this end point

    Secondary: Number of Subjects With Positive Anti-Drug Antibody (ADA) Titer

    Close Top of page
    End point title
    Number of Subjects With Positive Anti-Drug Antibody (ADA) Titer [12]
    End point description
    Number of subjects with positive sample(s) in the ADA assay and in the neutralizing anti-drug antibodies (NAb) assay. An endpoint titer less than (<) 6.64 corresponded to negative ADA category value. This analysis included all enrolled subjects with ESFT and who started treatment with figitumumab. None of the serum samples were positive for ADAs following repeated administration of figitumumab, as indicated by an endpoint titer of <6.64.
    End point type
    Secondary
    End point timeframe
    Cycle 4 (predose on Day 1), 28 days after last dose (End-of-Treatment), and follow-up (approximately 150 days after last dose)
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: This end point  was planned to be assessed for subjects in "Figitumumab 30 mg/kg (Phase 2)" reporting arm only.
    End point values
    Figitumumab 30 mg/kg (Phase 2)
    Number of subjects analysed
    107
    Units: subjects
        number (not applicable)
    0
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Baseline up to 150 days after last dose of study drug
    Adverse event reporting additional description
    The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.1
    Reporting groups
    Reporting group title
    Figitumumab 30mg/kg (Phase 2)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle) until unacceptable toxicity or participant withdrawal, for up to 6 cycles.

    Reporting group title
    Figitumumab 30 mg/kg + Rapamycin (Phase 2)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

    Reporting group title
    Figitumumab 30 mg/kg Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

    Reporting group title
    Figitumumab 30 mg/kg Dose Extension (Phase 1B)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle).

    Reporting group title
    Figitumumab 20 mg/kg Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle).

    Reporting group title
    Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

    Reporting group title
    Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab 30 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

    Reporting group title
    Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)
    Reporting group description
    Figitumumab 20 mg/kg IV was administered every 4 weeks (1 cycle). As optional salvage therapy for disease progression, oral rapamycin at 2 to 4 mg/day was administered in combination with figitumumab.

    Serious adverse events
    Figitumumab 30mg/kg (Phase 2) Figitumumab 30 mg/kg + Rapamycin (Phase 2) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B) Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B) Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1) Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)
    Total subjects affected by serious adverse events
         subjects affected / exposed
    47 / 107 (43.93%)
    16 / 29 (55.17%)
    3 / 6 (50.00%)
    10 / 21 (47.62%)
    2 / 4 (50.00%)
    7 / 9 (77.78%)
    3 / 4 (75.00%)
    0 / 1 (0.00%)
         number of deaths (all causes)
    33
    11
    2
    9
    2
    5
    3
    0
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Neoplasm progression
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Metastatic neoplasm
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukaemia
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Haematoma
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Superior vena cava syndrome
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Medical device complication
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disease progression
         subjects affected / exposed
    22 / 107 (20.56%)
    12 / 29 (41.38%)
    1 / 6 (16.67%)
    6 / 21 (28.57%)
    2 / 4 (50.00%)
    3 / 9 (33.33%)
    2 / 4 (50.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 36
    0 / 15
    0 / 2
    0 / 6
    0 / 4
    0 / 4
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 24
    0 / 10
    0 / 1
    0 / 7
    0 / 0
    0 / 2
    0 / 2
    0 / 0
    Pyrexia
         subjects affected / exposed
    4 / 107 (3.74%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Pelvic pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Apnoea
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atelectasis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    Cough
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wheezing
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Haemoglobin decreased
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Wound dehiscence
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Convulsion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrospinal fluid leakage
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Central nervous system haemorrhage
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Paraesthesia
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intracranial hypotension
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    2 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal obstruction
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematemesis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    1 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Bone pain
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscle spasms
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Infection
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung infection
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acinetobacter infection
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningitis bacterial
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia streptococcal
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory syncytial virus infection
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercalcaemia
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Figitumumab 30mg/kg (Phase 2) Figitumumab 30 mg/kg + Rapamycin (Phase 2) Figitumumab 30 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg Dose Extension (Phase 1B) Figitumumab 20 mg/kg Dose Escalation (Phase 1) Figitumumab 30 mg/kg + Rapamycin Dose Extension (Phase 1B) Figitumumab 30 mg/kg + Rapamycin Dose Escalation (Phase 1) Figitumumab 20 mg/kg + Rapamycin Dose Escalation (Phase 1)
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    99 / 107 (92.52%)
    29 / 29 (100.00%)
    6 / 6 (100.00%)
    19 / 21 (90.48%)
    3 / 4 (75.00%)
    9 / 9 (100.00%)
    3 / 4 (75.00%)
    1 / 1 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Tumour pain
         subjects affected / exposed
    7 / 107 (6.54%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    8
    0
    0
    0
    0
    0
    0
    0
    Tumour haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Vascular disorders
    Pallor
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Orthostatic hypotension
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypotension
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hot flush
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Flushing
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Hypertension
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Vasodilatation
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Surgical and medical procedures
    Amputation
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    General disorders and administration site conditions
    Injection site extravasation
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Impaired healing
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Influenza like illness
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    General physical health deterioration
         subjects affected / exposed
    4 / 107 (3.74%)
    5 / 29 (17.24%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    8
    0
    0
    0
    0
    0
    0
    Condition aggravated
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Chest pain
         subjects affected / exposed
    15 / 107 (14.02%)
    4 / 29 (13.79%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    24
    5
    0
    0
    0
    0
    0
    0
    Asthenia
         subjects affected / exposed
    13 / 107 (12.15%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    0
    0
    0
    0
    0
    0
    0
    Catheter site pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Fatigue
         subjects affected / exposed
    27 / 107 (25.23%)
    10 / 29 (34.48%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    36
    12
    0
    0
    0
    0
    0
    0
    Pyrexia
         subjects affected / exposed
    13 / 107 (12.15%)
    7 / 29 (24.14%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    14
    8
    0
    0
    0
    0
    0
    0
    Pain
         subjects affected / exposed
    5 / 107 (4.67%)
    4 / 29 (13.79%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    4
    0
    0
    0
    0
    0
    0
    Peripheral swelling
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Oedema peripheral
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Malaise
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Mucosal inflammation
         subjects affected / exposed
    4 / 107 (3.74%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    3
    0
    0
    0
    0
    0
    0
    Mucosal dryness
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Medical device complication
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Mucous membrane disorder
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Swelling
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Social circumstances
    Immobile
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Reproductive system and breast disorders
    Menstruation irregular
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Erectile dysfunction
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Dysmenorrhoea
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Amenorrhoea
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    2
    0
    0
    0
    0
    0
    0
    Vulvovaginal pruritus
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Vaginal haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Testicular pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Scrotal swelling
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Pelvic pain
         subjects affected / exposed
    4 / 107 (3.74%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    0
    0
    Ovarian cyst
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Perineal erythema
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Alveolitis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Cough
         subjects affected / exposed
    17 / 107 (15.89%)
    9 / 29 (31.03%)
    1 / 6 (16.67%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    24
    15
    1
    2
    0
    2
    0
    0
    Pleuritic pain
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    1
    0
    0
    0
    0
    0
    0
    Pleural effusion
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    1
    0
    0
    0
    0
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    5 / 107 (4.67%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    3
    0
    2
    0
    1
    0
    0
    Hypopnoea
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Nasal congestion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Pneumothorax
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    0
    0
    0
    Epistaxis
         subjects affected / exposed
    8 / 107 (7.48%)
    4 / 29 (13.79%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    3 / 9 (33.33%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    10
    5
    0
    1
    0
    3
    0
    0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Dyspnoea
         subjects affected / exposed
    16 / 107 (14.95%)
    8 / 29 (27.59%)
    0 / 6 (0.00%)
    4 / 21 (19.05%)
    0 / 4 (0.00%)
    4 / 9 (44.44%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    18
    11
    0
    4
    0
    8
    0
    0
    Dysphonia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Haemoptysis
         subjects affected / exposed
    3 / 107 (2.80%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    2
    0
    1
    0
    1
    0
    0
    Wheezing
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Pulmonary pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Tachypnoea
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    3
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    0
    Respiratory tract congestion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Rales
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Throat irritation
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Hypoxia
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Painful respiration
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Pneumomediastinum
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Psychiatric disorders
    Sleep disorder
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Insomnia
         subjects affected / exposed
    2 / 107 (1.87%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    2
    0
    0
    0
    0
    0
    0
    Fear
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Depression
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Agitation
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Anxiety
         subjects affected / exposed
    6 / 107 (5.61%)
    4 / 29 (13.79%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    4
    0
    0
    0
    0
    0
    0
    Mood altered
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Investigations
    Breath sounds abnormal
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Brain natriuretic peptide increased
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Blood uric acid increased
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    0
    0
    0
    0
    0
    0
    0
    Blood urea increased
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Blood creatinine increased
         subjects affected / exposed
    4 / 107 (3.74%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    1
    0
    0
    0
    0
    0
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    5 / 107 (4.67%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    2
    0
    0
    0
    0
    0
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    4 / 107 (3.74%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    1
    0
    0
    0
    0
    0
    0
    Alanine aminotransferase increased
         subjects affected / exposed
    6 / 107 (5.61%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    11
    2
    0
    0
    0
    0
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    White blood cell count decreased
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    0
    0
    0
    0
    0
    0
    0
    Weight decreased
         subjects affected / exposed
    13 / 107 (12.15%)
    10 / 29 (34.48%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    20
    12
    0
    0
    0
    0
    0
    0
    Transaminases increased
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    0
    0
    Right ventricular systolic pressure increased
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Ejection fraction decreased
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Haemoglobin decreased
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    1
    0
    0
    0
    0
    0
    0
    Haemoglobin abnormal
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    11 / 107 (10.28%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    18
    4
    0
    0
    0
    0
    0
    0
    Electrocardiogram ST segment depression
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    N-terminal prohormone brain natriuretic peptide increased
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Weight increased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Hepatic enzyme increased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    C-reactive protein increased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Breath sounds
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Blood sodium decreased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Sunburn
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Post procedural complication
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Infusion related reaction
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Humerus fracture
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Excoriation
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Contusion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Fall
         subjects affected / exposed
    0 / 107 (0.00%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    Thermal burn
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Tibia fracture
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Stress fracture
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Congenital, familial and genetic disorders
    Cerebral palsy
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    5 / 107 (4.67%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    9
    0
    0
    0
    1
    1
    0
    0
    Supraventricular extrasystoles
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Sinus bradycardia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Pericardial effusion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Bradycardia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    1
    0
    0
    0
    Left ventricular dysfunction
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Tricuspid valve incompetence
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Ventricular extrasystoles
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Nervous system disorders
    Convulsion
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Disturbance in attention
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Dizziness
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    1
    0
    0
    0
    0
    0
    0
    Balance disorder
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Memory impairment
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Lethargy
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Intraventricular haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypotonia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypoaesthesia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Hemiparesis
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Headache
         subjects affected / exposed
    19 / 107 (17.76%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    28
    2
    0
    0
    0
    0
    0
    0
    Facial paresis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Dyskinesia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Dysgeusia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Sensory loss
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Peripheral sensorimotor neuropathy
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Parosmia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Paraplegia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Paraparesis
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Monoparesis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Neuropathy peripheral
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Neuralgia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Motor dysfunction
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Monoplegia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Paraesthesia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Somnolence
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    0
    0
    Tremor
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Syncope
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Spinal cord compression
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    VIIth nerve paralysis
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    14 / 107 (13.08%)
    9 / 29 (31.03%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    1 / 4 (25.00%)
    1 / 1 (100.00%)
         occurrences all number
    26
    11
    0
    3
    0
    1
    5
    3
    Bone marrow failure
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Bone marrow oedema
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Leukocytosis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Leukopenia
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Thrombocytopenia
         subjects affected / exposed
    13 / 107 (12.15%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    2 / 4 (50.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    4
    0
    3
    2
    1
    0
    0
    Pancytopenia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Neutropenia
         subjects affected / exposed
    5 / 107 (4.67%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    0
    0
    0
    0
    0
    0
    0
    Lymphopenia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    1
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    1
    0
    0
    0
    0
    0
    0
    Tinnitus
         subjects affected / exposed
    5 / 107 (4.67%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    0
    0
    0
    0
    0
    0
    0
    Hypoacusis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Vertigo positional
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Ear pain
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Ear discomfort
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    1
    0
    0
    0
    0
    Eye disorders
    Vision blurred
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    1
    0
    0
    0
    0
    Conjunctival haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Conjunctival hyperaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Dry eye
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Eye pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    Eye pruritus
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    1
    0
    0
    0
    0
    0
    Lacrimation increased
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Ocular hyperaemia
         subjects affected / exposed
    15 / 107 (14.02%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    5 / 21 (23.81%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    0
    1
    5
    0
    0
    0
    0
    Pupils unequal
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Scleral hyperaemia
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Visual impairment
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    3
    0
    0
    0
    0
    0
    0
    Eye movement disorder
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Gastrointestinal disorders
    Dyspepsia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    2
    1
    0
    0
    0
    Abdominal distension
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Dry mouth
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    Diarrhoea
         subjects affected / exposed
    15 / 107 (14.02%)
    2 / 29 (6.90%)
    2 / 6 (33.33%)
    5 / 21 (23.81%)
    1 / 4 (25.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    19
    4
    3
    7
    1
    4
    0
    0
    Abdominal discomfort
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Constipation
         subjects affected / exposed
    20 / 107 (18.69%)
    9 / 29 (31.03%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    3 / 9 (33.33%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    22
    11
    0
    2
    0
    3
    1
    0
    Aphthous stomatitis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    5 / 107 (4.67%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    3
    0
    1
    0
    2
    0
    0
    Abdominal pain
         subjects affected / exposed
    8 / 107 (7.48%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    8
    3
    0
    0
    2
    1
    0
    0
    Dental caries
         subjects affected / exposed
    1 / 107 (0.93%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    2
    0
    0
    0
    0
    0
    0
    Dysphagia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Faecal incontinence
         subjects affected / exposed
    2 / 107 (1.87%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    2
    0
    0
    0
    0
    0
    0
    Gastritis
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 107 (0.00%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    3
    0
    0
    0
    0
    0
    0
    Gingival bleeding
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Gingival pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Gingival recession
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Haematemesis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Haemorrhoids
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    0
    0
    Haematochezia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Stomatitis
         subjects affected / exposed
    3 / 107 (2.80%)
    6 / 29 (20.69%)
    1 / 6 (16.67%)
    3 / 21 (14.29%)
    0 / 4 (0.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    7
    1
    3
    0
    2
    0
    0
    Rectal haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Oral pain
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Oesophageal pain
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Odynophagia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Nausea
         subjects affected / exposed
    16 / 107 (14.95%)
    9 / 29 (31.03%)
    2 / 6 (33.33%)
    6 / 21 (28.57%)
    1 / 4 (25.00%)
    2 / 9 (22.22%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    18
    10
    4
    7
    1
    2
    0
    0
    Mouth ulceration
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    2
    0
    1
    0
    0
    0
    0
    Mouth haemorrhage
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypoaesthesia oral
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Toothache
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Tooth discolouration
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Vomiting
         subjects affected / exposed
    17 / 107 (15.89%)
    9 / 29 (31.03%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    12
    0
    0
    0
    0
    0
    0
    Cheilitis
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Lip dry
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    Retching
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Hepatobiliary disorders
    Jaundice
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Dermatitis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Alopecia
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    1
    0
    0
    Acne
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Psoriasis
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Pruritus
         subjects affected / exposed
    7 / 107 (6.54%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    1
    0
    0
    0
    0
    0
    0
    Photosensitivity reaction
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Nail disorder
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Dry skin
         subjects affected / exposed
    5 / 107 (4.67%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    1
    0
    0
    0
    0
    0
    0
    Hirsutism
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hair growth abnormal
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    1
    0
    0
    0
    0
    0
    0
    Erythema
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Ingrowing nail
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Rash
         subjects affected / exposed
    6 / 107 (5.61%)
    4 / 29 (13.79%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    5
    0
    0
    0
    0
    0
    0
    Skin lesion
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    Exfoliative rash
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Petechiae
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    Rash papular
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    Scar pain
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Skin irritation
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Subcutaneous emphysema
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Decubitus ulcer
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Renal colic
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Proteinuria
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Polyuria
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Bladder spasm
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Micturition disorder
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Leukocyturia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Haematuria
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Dysuria
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Pollakiuria
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Renal failure acute
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Urinary retention
         subjects affected / exposed
    0 / 107 (0.00%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    Urinary incontinence
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Urinary hesitation
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Renal failure chronic
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Vesicoureteric reflux
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Renal impairment
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Endocrine disorders
    Cushingoid
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Inappropriate antidiuretic hormone secretion
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    1 / 4 (25.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    11 / 107 (10.28%)
    5 / 29 (17.24%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    14
    7
    0
    0
    0
    0
    0
    0
    Muscle spasms
         subjects affected / exposed
    20 / 107 (18.69%)
    5 / 29 (17.24%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    27
    6
    0
    0
    0
    0
    0
    0
    Muscular weakness
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Musculoskeletal pain
         subjects affected / exposed
    11 / 107 (10.28%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    12
    5
    0
    0
    0
    0
    0
    0
    Muscle disorder
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    2
    0
    0
    0
    0
    0
    0
    Back pain
         subjects affected / exposed
    17 / 107 (15.89%)
    8 / 29 (27.59%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    16
    0
    0
    0
    0
    0
    0
    Bone pain
         subjects affected / exposed
    4 / 107 (3.74%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    3
    0
    0
    0
    0
    0
    0
    Bone swelling
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Joint swelling
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    Musculoskeletal chest pain
         subjects affected / exposed
    7 / 107 (6.54%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    4
    0
    0
    0
    0
    0
    0
    Myalgia
         subjects affected / exposed
    8 / 107 (7.48%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    8
    3
    0
    0
    0
    0
    0
    0
    Neck pain
         subjects affected / exposed
    4 / 107 (3.74%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    2
    0
    0
    0
    0
    0
    0
    Pain in extremity
         subjects affected / exposed
    9 / 107 (8.41%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    9
    3
    0
    0
    0
    0
    0
    0
    Spinal disorder
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Groin pain
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    Mobility decreased
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    Infections and infestations
    Conjunctivitis
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    2 / 21 (9.52%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    2
    0
    0
    0
    0
    Candida infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Device related infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Bronchitis
         subjects affected / exposed
    4 / 107 (3.74%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    0
    0
    Gingivitis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Gastroenteritis
         subjects affected / exposed
    2 / 107 (1.87%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    2
    0
    0
    0
    0
    0
    0
    Bronchopneumonia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Oral fungal infection
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Oral candidiasis
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    5 / 107 (4.67%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    2
    0
    0
    0
    0
    0
    0
    Lung infection
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    4
    0
    0
    0
    0
    0
    0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    H1N1 influenza
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Laryngitis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Influenza
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Infection
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Herpes zoster
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Localised infection
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Skin infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Otitis media acute
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Otitis media
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Oral herpes
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Sinusitis
         subjects affected / exposed
    6 / 107 (5.61%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    6
    1
    0
    0
    0
    0
    0
    0
    Papilloma viral infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Respiratory tract infection
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Post procedural infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Pharyngitis
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Paronychia
         subjects affected / exposed
    4 / 107 (3.74%)
    3 / 29 (10.34%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    7
    6
    0
    0
    0
    0
    0
    0
    Rhinitis
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    5 / 107 (4.67%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    0
    0
    0
    0
    0
    0
    0
    Viral infection
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Urinary tract infection
         subjects affected / exposed
    4 / 107 (3.74%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    1
    0
    0
    0
    0
    0
    0
    Wound infection
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Viral upper respiratory tract infection
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    1 / 21 (4.76%)
    0 / 4 (0.00%)
    1 / 9 (11.11%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    0
    Pneumonia primary atypical
         subjects affected / exposed
    0 / 107 (0.00%)
    0 / 29 (0.00%)
    1 / 6 (16.67%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    1 / 4 (25.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    1
    0
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    12 / 107 (11.21%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    17
    2
    0
    0
    0
    0
    0
    0
    Hypermagnesaemia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    0
    0
    Hyperphosphataemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Decreased appetite
         subjects affected / exposed
    22 / 107 (20.56%)
    13 / 29 (44.83%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    24
    17
    0
    0
    0
    0
    0
    0
    Acidosis
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    0
    Dehydration
         subjects affected / exposed
    1 / 107 (0.93%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    2
    0
    0
    0
    0
    0
    0
    Hyperalbuminaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypercalcaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Cachexia
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Hyperuricaemia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypoalbuminaemia
         subjects affected / exposed
    4 / 107 (3.74%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    1
    0
    0
    0
    0
    0
    0
    Hypocalcaemia
         subjects affected / exposed
    2 / 107 (1.87%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    1
    0
    0
    0
    0
    0
    0
    Hypophagia
         subjects affected / exposed
    1 / 107 (0.93%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Hypokalaemia
         subjects affected / exposed
    2 / 107 (1.87%)
    2 / 29 (6.90%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    4
    0
    0
    0
    0
    0
    0
    Hyponatraemia
         subjects affected / exposed
    3 / 107 (2.80%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    4
    0
    0
    0
    0
    0
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    3 / 107 (2.80%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    5
    1
    0
    0
    0
    0
    0
    0
    Polydipsia
         subjects affected / exposed
    2 / 107 (1.87%)
    0 / 29 (0.00%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    Tetany
         subjects affected / exposed
    0 / 107 (0.00%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Type 1 diabetes mellitus
         subjects affected / exposed
    1 / 107 (0.93%)
    1 / 29 (3.45%)
    0 / 6 (0.00%)
    0 / 21 (0.00%)
    0 / 4 (0.00%)
    0 / 9 (0.00%)
    0 / 4 (0.00%)
    0 / 1 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    18 Jun 2008
    A secondary objective of collection of a blood samples for the enumeration of circulating tumor cells expressing the IGF-IR (surface protein and gene copy number) was added. Option of local therapy (such as radiation and/or surgery) in patients with durable objective responses and optional salvage therapy in combination with Rapamycin only to patients with progressive disease was added and collection of safety information about the combination of figitumumab with rapamycin was added. Valvular disease and endocarditis were added to the list of significant cardiac diseases which would preclude enrollment in the study. Additional information on the analysis of the tumor biopsies and the collection of the tumor specimens was included in the protocol.
    10 Mar 2009
    Enrollment of diabetic patients (with properly managed diabetic condition) into the study was added. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was updated according to the current standard medical practice. Safety follow up visits scheduled once every other a month for up to 150 days after the last study drug administration, unless the patient withdraws consent or start a new anti-cancer treatment was added. Additional follow up study visits to monitor for any sustained, treatment emergent adverse events and patients discontinuing therapy without evidence of tumor progression were assessed every 8 weeks until disease progression even if new anticancer therapy was initiated, were added to the protocol.
    08 Dec 2010
    The protocol was amended to provide guidance for evaluation and reportability of potential cases of liver injury and clarification about preparation and administration of study drug was provided.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:12:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA